Article
Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial.
Lung cancer (Amsterdam, Netherlands) - 1 Sept 2020
Fan Yun, Chen Jianhua, Zhou Chengzhi, Wang Huijuan, Shu Yongqian, Zhang Jacky, Hua Hairui, Huang Dennis Chin-Lun, Zhou Caicun
Abstract excerpt
BACKGROUND: Despite 1-4 % of NSCLC tumors harboring mutations in the HER2 gene, there are no approved HER2-pathway-targeted treatments available. We report an open-label, single-arm, multicenter phase II study investigating the efficacy and safety of afatinib in Asian patients with HER2-mutation positive (HER2m+) NSCLC. METHODS: Eligible patients for Part A had confirmed stage IIIb/IV HER2m + NSCLC, had failed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.